Good evening :)
Place Order
Add to Watchlist

Remedium Lifecare Ltd

REMLIFE

Remedium Lifecare Ltd

REMLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹209 cr, stock is ranked 2,476
High RiskStock is 5.02x as volatile as Nifty
5.220.38% (+0.02)
5.220.38% (+0.02)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹209 cr, stock is ranked 2,476
High RiskStock is 5.02x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

High

Strong financials and growth story over the years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹209 cr, stock is ranked 2,476
High RiskStock is 5.02x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
11.725.04
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.716.630.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

0

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 595.31%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0% to 1.08%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue4.261.430.370.252.8990.03504.79509.844,062.793,365.17
Raw Materialssubtract3.650.710.140.000.000.000.00417.304,127.293,320.93
Power & Fuel Costsubtract0.080.080.020.000.050.070.090.060.06
Employee Costsubtract0.050.040.130.040.180.190.210.550.40
Selling & Administrative Expensessubtract0.200.130.050.000.471.093.766.464.95
Operating & Other expensessubtract0.250.470.010.191.7987.96498.9177.46-125.20
Depreciation/Amortizationsubtract0.010.000.000.000.010.060.070.150.060.04
Interest & Other Itemssubtract0.010.000.000.000.010.020.230.454.786.69
Taxes & Other Itemssubtract0.000.000.000.020.090.170.451.9717.7219.03
EPS0.000.000.00-0.000.010.010.030.131.484.58
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Remedium Lifecare Ltd6.625.04
Sun Pharmaceutical Industries Ltd45.126.440.75%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd69.1016.690.83%

Price Comparison

Compare REMLIFE with any stock or ETF
Compare REMLIFE with any stock or ETF
REMLIFE
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 7.87%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding1.11%0.00%0.00%0.00%98.89%

Mar 2024

Jun 2024

Jul 2024

Sep 2024

Shareholding History

SepDec '23MarJunJulSep0.08%0.04%0.04%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

REMLIFE has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Remedium Lifecare standalone net profit declines 72.74% in the September 2024 quarter

Net profit of Remedium Lifecare declined 72.74% to Rs 1.78 crore in the quarter ended September 2024 as against Rs 6.53 crore during the previous quarter ended September 2023. Sales declined 94.65% to Rs 25.08 crore in the quarter ended September 2024 as against Rs 468.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales25.08468.57 -95 OPM %17.781.35 - PBDT2.4710.42 -76 PBT2.4610.41 -76 NP1.786.53 -73 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Remedium Lifecare to declare Quarterly Result

Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Remedium Lifecare postpones board meeting

Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 3 September 2024. The meeting will now be held on 4 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Remedium Lifecare to convene board meeting

Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Remedium Lifecare standalone net profit declines 68.76% in the June 2024 quarter

Net profit of Remedium Lifecare declined 68.76% to Rs 1.64 crore in the quarter ended June 2024 as against Rs 5.25 crore during the previous quarter ended June 2023. Sales declined 76.49% to Rs 77.70 crore in the quarter ended June 2024 as against Rs 330.46 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales77.70330.46 -76 OPM %0.502.20 - PBDT2.287.28 -69 PBT2.277.27 -69 NP1.645.25 -69 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Remedium Lifecare postpones board meeting

Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 8 August 2024. The meeting will now be held on 14 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Remedium Lifecare to acquire technology for manufacturing lithium carbonate in India

Remedium Lifecare has entered into a strategic agreement with Angel Partners, UK, effective 29 July  2024, to acquire technology for manufacturing lithium carbonate in India. The company has also signed an annual Supply Agreement with Alfa Chemicals and Solvents, Turkey, effective the same date. Supplies of technical-grade lithium carbonate will commence in the January-March 2025 quarter. The supplies for CY 2025 are valued at USD 20-25 million. Technical-grade lithium carbonate is used in lithium-ion batteries for electric vehicles and portable electronics. Remedium has partnered with various contract manufacturers to produce technical-grade lithium carbonate using the technology from Angel Partners. Powered by Capital Market - Live

4 months agoCapital Market - Live

Remedium Lifecare Ltd leads losers in ‘B’ group

5 months agoBusiness Standard
Spotlight
Remedium Lifecare Ltd leads losers in 'B' group

Ksolves India Ltd, National Peroxide Ltd, Aarti Surfactants Ltd and Jasch Gauging Technologies Ltd are among the other losers in the BSE's 'B' group today, 22 July 2024.Remedium Lifecare Ltd crashed 10.33% to Rs 16.76 at 14:32 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 49.55 lakh shares were traded on the counter so far as against the average daily volumes of 38.14 lakh shares in the past one month.Ksolves India Ltd lost 8.60% to Rs 1104.55. The stock was the second biggest loser in 'B' group.On the BSE, 28586 shares were traded on the counter so far as against the average daily volumes of 6376 shares in the past one month.National Peroxide Ltd tumbled 8.29% to Rs 1059. The stock was the third biggest loser in 'B' group.On the BSE, 19625 shares were traded on the counter so far as against the average daily volumes of 9819 shares in the past one month.Aarti Surfactants Ltd slipped 7.05% to Rs 646.6. The stock was the fourth biggest loser in 'B' group.On the BSE, 3877 shares were traded on the counter so far as against the average daily volumes of 4280 shares in the past one month.Jasch Gauging Technologies Ltd pared 6.37% to Rs 728. The stock was the fifth biggest loser in 'B' group.On the BSE, 11470 shares were traded on the counter so far as against the average daily volumes of 6862 shares in the past one month.Powered by Capital Market - Live

5 months agoCapital Market - Live

Krebs Biochemicals & Industries Ltd leads gainers in ‘B’ group

5 months agoBusiness Standard